The deal was signed at the end of last year and will see Allevi provide 3D bioprinters and bioink while Lonza will add its primary cells, stem cells and cell culture media capabilities to the partnership.
Between the two companies’ offerings, researchers will have access to 3D bioprinting of living tissue that can be used in the drug discovery process and in tissue engineering.
With the addition of Lonza’s materials, Allevi will be able to offer a combined package to its customers.
Allevi was founded in 2014 and offers desktop 3D bioprinters, with its website stating that its technology is used in hundreds of labs across the globe. Included within this pool of researchers are companies such as AbbVie, GSK, and Johnson & Johnson.
Over the last decade, as 3D bioprinting technology has improved, it is becoming of greater interest for researchers to test drug compounds on printed organs and tissues.
Just over a year ago, Celprogen used 3D printed brains to identify and characterize 11 potential drug candidates for the treatment of neurological disorders.
While Brinter recently developed and made commercially available a 3D bioprinter that can be used for the testing of the toxicity of drug compounds.